QLS5132 Combination Therapy in Advanced Solid Tumors

NCT07453394 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

626

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer (GC)
Non-small Cell Lung Cancer (NSCLC)
Endometrial Cancer
Advanced Solid Tumors
Ovarian Cancer

Interventions

DRUG: QLS5132; Bevacizumab
DRUG: QLS5132; Platinum; Bevacizumab
DRUG: QLS5132; Olaparib; Bevacizumab
DRUG: QLS5132; QL1706; QL2107
DRUG: QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin

Sponsor

Qilu Pharmaceutical Co., Ltd.